452 related articles for article (PubMed ID: 25764010)
1. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
3. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
Lee YS; Nam HS; Lim JH; Kim JS; Moon Y; Cho JH; Ryu JS; Kwak SM; Lee HL
BMC Cancer; 2017 Aug; 17(1):557. PubMed ID: 28830378
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion.
Lim JU; Yeo CD; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Lee SH
PLoS One; 2018; 13(7):e0200341. PubMed ID: 30005083
[TBL] [Abstract][Full Text] [Related]
10. Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion.
Lim JU; Yeo CD; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Lee SH
Sci Rep; 2019 Mar; 9(1):4721. PubMed ID: 30886226
[TBL] [Abstract][Full Text] [Related]
11. Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non-small-cell lung cancer.
Wang J; Fu J; Shen Q; Zhang F; Wang Y; Wu LL
J Clin Lab Anal; 2019 Sep; 33(7):e22943. PubMed ID: 31268191
[TBL] [Abstract][Full Text] [Related]
12. Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion.
Verma A; Phua CK; Sim WY; Algoso RE; Tee KS; Lew SJ; Lim AY; Goh SK; Tai DY; Kor AC; Ho B; Abisheganaden J
Medicine (Baltimore); 2016 Jun; 95(26):e3996. PubMed ID: 27368006
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.
Zhang Y; Yu LK; Lu GJ; Xia N; Xie HY; Hu W; Hao KK; Xu CH; Qian Q
Asian Pac J Cancer Prev; 2014; 15(19):8435-40. PubMed ID: 25339042
[TBL] [Abstract][Full Text] [Related]
14. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
[TBL] [Abstract][Full Text] [Related]
15. Clinical course of non-small cell lung cancer patients with dry pleural dissemination: Retrospective observational study.
Kim W; Park IK; Park S; Kang CH; Kim YT
Medicine (Baltimore); 2020 Mar; 99(11):e19533. PubMed ID: 32176106
[TBL] [Abstract][Full Text] [Related]
16. Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival.
Lumachi F; Mazza F; Ermani M; Chiara GB; Basso SM
Anticancer Res; 2012 Nov; 32(11):5071-4. PubMed ID: 23155281
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Kitamura K; Kubota K; Ando M; Takahashi S; Nishijima N; Sugano T; Toyokawa M; Miwa K; Kosaihira S; Noro R; Minegishi Y; Seike M; Yoshimura A; Gemma A
Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
[TBL] [Abstract][Full Text] [Related]
18. Malignant Pleural Effusion at Presentation in Patients with Small-Cell Lung Cancer.
Shojaee S; Singh I; Solsky I; Nana-Sinkam P
Respiration; 2019; 98(3):198-202. PubMed ID: 31121583
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status?
Abrao FC; Peixoto RD; de Abreu IR; Janini MC; Viana GG; de Oliveira MC; Younes RN
J Surg Oncol; 2016 Apr; 113(5):570-4. PubMed ID: 26751412
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer patients with malignant pleural effusions.
Park DS; Kim D; Hwang KE; Hwang YR; Park C; Seol CH; Cho KH; Kim BR; Park SH; Jeong ET; Kim HR
Yonsei Med J; 2013 Mar; 54(2):396-402. PubMed ID: 23364973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]